MedTrace Logo

The Influence of Vertical Implant Position With Immediate Provisionalization on the Marginal Bone Loss.

NCT05973357 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-08-02

No results posted yet for this study

Summary

Multiple clinical studies have established high survival rates and tremendous predictability of dental implant treatment. However, a pleasant esthetic outcome is the patient's primary expectation regarding implants in the esthetic zone and several esthetic factors have been evaluated to contribute to an esthetic appearance. Among these, the midfacial soft tissue level is considered to be one of the most important factors; Cosyn and co-workers reported that among factors including soft tissue phenotype, the midfacial recession was associated with the position of the implant .

Therefore, subcrestal implant placement has been advocated as it has been associated with the reduction of crestal bone loss in cases with decreased soft tissue thickness. If the vertical soft tissues on the crest of the alveolar ridge are 2 mm or less at the time of implant placement, implants will undergo unavoidable bone resorption by establishing sufficient biologic protection. Another option was proposed by Linkevicius et al, who introduced the subcrestal implant placement as a method to accommodate the problem of thin soft tissues.

Research question:

Does the placement of delayed implants with different vertical depth affect the marginal bone loss with immediate provisionalization?

Conditions

  • Dental Implant Failed
  • Implant Site Reaction

Interventions

PROCEDURE

Sub-crestal implant

Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization

PROCEDURE

Equi-crestal implant

Patients receiving delayed implant placed equi-crestal level with immediate provisionalization

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-20
Primary Completion
2025-09-20
Completion
2025-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05973357 on ClinicalTrials.gov